OBJECTIVE: The objective of this study was to evaluate donepezil, an acetylcholinesterase inhibitor, in the treatment of frontotemporal dementia (FTD). METHODS: Twelve patients with FTD who received donepezil for six months were compared with 12 FTD controls on behavioral measures. RESULTS: The groups did not differ on most variables at baseline or at six months; however, the donepezil group had greater worsening on the FTD Inventory. Four treated patients had increased disinhibited or compulsive acts, which abated with discontinuation of the medication. CONCLUSION: There were no changes in global cognitive performance or dementia severity; however, a subgroup of patients with FTD can experience worsening of symptoms with donepezil.
OBJECTIVE: The objective of this study was to evaluate donepezil, an acetylcholinesterase inhibitor, in the treatment of frontotemporal dementia (FTD). METHODS: Twelve patients with FTD who received donepezil for six months were compared with 12 FTD controls on behavioral measures. RESULTS: The groups did not differ on most variables at baseline or at six months; however, the donepezil group had greater worsening on the FTD Inventory. Four treated patients had increased disinhibited or compulsive acts, which abated with discontinuation of the medication. CONCLUSION: There were no changes in global cognitive performance or dementia severity; however, a subgroup of patients with FTD can experience worsening of symptoms with donepezil.
Authors: Roy Yaari; Helle Brand; James D Seward; Anna D Burke; Adam S Fleisher; Jan Dougherty; Pierre N Tariot Journal: Prim Care Companion CNS Disord Date: 2011
Authors: Maria Carmela Tartaglia; Bei Hu; Kala Mehta; John Neuhaus; Kristine Yaffe; Bruce L Miller; Adam Boxer Journal: Alzheimer Dis Assoc Disord Date: 2014 Apr-Jun Impact factor: 2.703